p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy

作者：Dong Hu, Xiaoshuang Lyu, Zheqi Li, Prasanna Ekambaram, Anushka Dongre, Tanner J. Freeman, Marion Joy, Jennifer M. Atkinson, Daniel D. Brown, Zongyou Cai, Neil Carleton, Hannah E. Crentsil, John R. Little, Felicia Kemp, Linda R. Klei, Maria Beecher, Jeff Sperinde, Weidong Huang, Heikki Joensuu, Ashok Srinivasan, Katherine L. Pogue–Geile, Ying Wang, Huichen Feng, Lisa D. Eli, Alshad S. Lalani, Jian Zou, George C. Tseng, Tullia C. Bruno, Adrian V. Lee, Steffi Oesterreich, Norman Wolmark, Carmen J. Allegra, Samuel A. Jacobs, Linda M. McAllister‐Lucas, Peter C. Lucas · 发表于：Nature Cancer · 年份：2025 · DOI：10.1038/s43018-025-00969-4 · 被引用次数：13 · 研究领域：HER2/EGFR in Cancer Research、Monoclonal and Polyclonal Antibodies Research、Peptidase Inhibition and Analysis